Help
Options
Didn't know it?
click below
click below
Knew it?
click below
click below
Don't Know
Remaining cards (0)
Know
retry
shuffle
restart
0:00
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
Immunity
Caring for Patients with Immunity Concerns
| Term | Definition |
|---|---|
| Immune System Functions | Protect from foreign entities; identify and destroy harmful cells; remove debris. |
| Antigen | Foreign Substance, cell, toxin or protein causing immune system reaction |
| Immunocompetent | Body correctly identifies, destroys and removed inappropriate entities |
| Immunocompromised | a.k.a immunodeficient; body misidentifies or can not protect from inappropriate entities - over or under reacts |
| First Line of Immune Defenses | Surface (barrier) - Skin & Mucus membranes |
| Second Line of immune defenses | Cellular (nonspecific) - Phagocytes/Macrophages (destroy);Inflammatory responses (localizes; attracts phagocytes);Fever (weakens or destroys);Antimicrobial proteins (complement system);Interferons (mobilize immune system);Natural Killer Cells (cell lysis) |
| Third Line of immune defenses | Immune Response - Antibody-mediated immune response: humoral - B-lymphocytes (B-cells) Cell mediated immune response - T-Lymphocytes (T-Cells) |
| B-Lymphocytes (B-Cells) | Antibody-Mediated Immune Response: Humoral Activated by antigens and T-Cells Produce immunoglobulins |
| T-Lymphocytes (T-Cells) | Cell-Mediated immune response Attack viruses, bacterial & Malignant Cells Helper T-Cells (CD4 & T4 cells) stimulate the immune system Cytotoxic Cells: attack Antigens Suppressor T-Cells (T8): inhibit the immune system |
| Hypersensitivity | Abnormal, harmful response to antigen |
| Allergen | Exogenous antigen causing hypersensitivity reaction |
| Allergy | Hypersensitivity reaction to normally harmless substance; Mild to life threatening |
| Immediate response | Antigen-Antibody (I,II,III) |
| Delayed response | Antigen-lymphocyte (IV) |
| Type I Hypersensitivity Reaction | IgE-Mediated Hypersensitivity - IgE bound to mast cells and basophils degranulation: release histamine, acetylcholine, kinins, heparin, chemotactic factors ---> inflammatory response |
| IgE Mediated Hypersensitivity S & Sx | Uneasiness or sense of doom; hives; lightheadedness; itching palms or scalp; angioedema; uvula & larynx swelling; bronchial constriction; vasodilation & vascular permeability; increased gut permeability |
| Allergic Reactions - IgE mediated | asthma, conjunctivitis, rhinitis, hives |
| Anaphylaxis | acute, highly sensitive - vasodilation, increased capillary permeability; smooth muscle contraction; bronchial constriction |
| Anaphylactic shock | impaired tissue perfusion & hypotension from vasodilation and vascular fluid loss - Emergency mgmt = epinephrine SQ 1:1000; repeat in 15 min (IV=epi 1:100,000); tourniquet control, antihistamines, O2, bronchodilators |
| Type II hypersensitivity reaction | Cytotoxic Hypersensitivity - Reaction to foreign tissue or cell |
| Cytotoxic hypersensitivity (type II) | Common = hemolytic transfusion, graft or medication reaction; autoimmune IgG or IgM antibodies bind to antigen and initiate complement cascade; cell lysis and phagocytosis destroys antigen-bearing (ABO or Rh) target cells; killer T-Cells activated |
| Emergency Management for Cytotoxic (type II) reaction | Stop Transfusion or Rx, administer epinephrine, O2 & diuretics |
| Type III Hypersensitivity Reaction | Immune Complex-Mediated = circulating immune complexes are deposited in small vessels and extra-vascular tissues causing tissue damage (kidneys, lungs, joints) |
| Immune Complex-Mediated (type III) | Activates complement cascade, neutrophils, machrophages and mast cells. |
| Immune Complex-mediated reactions S & Sx | fever, rash, muscle pain, glomerulonephritis, lung inflammation |
| Immune Complex-mediated reactions treatment | For generalized reactions: "Serum sickness" (horse anti-tetanus toxoid = no longer used); penicillins, sulfonamides |
| Type IV hypersensitivity reactions | Delayed Hypersensitivity = cell mediated NOT antibody mediated Delayed NOT immediate (24-48 hours) |
| Delayed Hypersensitivity Reactions | Exaggerated antigen & cell-mediated reaction. lysozymes from macrophages and killer t-cells sx: edema, ischemia & tissue damage |
| Delayed Hypersensitivity Reaction Causes | Contact dermatitis, poision ivy, latex, +PPD - can escalate from Type IV (contact dermatitis) to Type I (anaphylaxis) with repeat exposure |
| Testing for Hypersensitivity Reactions | WBC Count with Diff (eosinophilia) ;RadioAllergoSorbenT Test (RAST) ;Blood type & Cross match (pre-transfusion); Complement & immune complexes assays:type III autoimmune disorders; Puncture,intradermal, patch testing; food diaries, elimination,re-intro |
| Indirect Coombs | Blood type & cross match - Circulating non-ABO antibodies |
| Direct Coombs | RBC-bound antibodies |
| Immunotherapy | aka desensitization aka hyposensitization: escalating exposure to dilute allergen |
| Plasmapheresis | removal of harmful components in plasma by passing the blood through a separator to remove immune complexes and return RBCs to patient |
| diphenhydramine (Benadryl) | antihistamine |
| epinephrine (adrenalin) | B-adrenergic sympathomimetics |
| cromolyn sodium (NasalCrom; Intal) | Mast Cell Stabalizer |
| prednisone (deltasone) | Steroids (glucocorticoids) |
| Common Nursing Dx for Hypersensitivity Reactions | Ineffective airway clearance, decreased cardiac output, risk for injury, knowledge deficit |
| Immune System Dysfunction | Impaired self-recognition treating 'self' as 'other' |
| Organ-specific | antibodies for specific tissues (hashimoto's thyroiditis) |
| Organ non-specific | results of reaction may concentrate in specific tissues (glomerulonephritis) |
| Systemic | multiple targets (rheumatoid arthritis; system lupus erythematosus) |
| Autoimmune disorder | genetic or familial component; females > males; overlap/multiple disorders; abnormal stressor precedes onset; progressive relapsing-remitting common |
| Medications for autoimmune disorders | Anti-inflammatory: ASA, NSAIDS, corticosteroids Anti-rheumatic: gold salts, DMARDS (methotrexate) Replacement: levothyroxine, insulin |
| Theories of Autoimmune disorders | Antigenic mimicry: 'self' and 'other' too close; changes in condition of host causing auto-antibody production; inadequate suppressor T-cells; excessive B-cell antibody production; mother-infant trans; viruses;release of sequestered antigens |
| Serological Assays | Antinuclear antibody (ANA): non-specific Lupus Erythematuosus cell test (LE): non-specific Rheumatoid factor (RF): blood:saline detection <1:20=elderly; 1:20-1:80= SLE, scleroderma, sclerosis, TB; >1:80=RA |
| Complement Assay | C1 through C9 counts & ratios |
| Common Nursing Diagnosis for AutoImmune Disorders | Activity intolerance, body image disturbance |
| HIV stands for ? | Human Immunodeficiency Virus |
| HIV Epidemiology in U.S. | U.S. 1.2 million (25% unaware) 60% = men sexually active with other men (MSM) 20% = men injection drug abuse 20% = women 75% heterosexual contact;25% IV drug abuse 1/2 of all HIV cases = African American Youth 15-24=40% new cases; adults >50=10% |
| HIV Epidemiology Globally | 33 million; 2.5 million new cases yearly; 2 million people die each year sub-saharan africa - 23 million eastern europe - 1.6 million Asia = 5 million (half in India) |
| HIV types | 2 Genetically distinct types : HIV1 & HIV2 - both zoomotic introductions (non-human primates) |
| Retrovirus | subgroup known as "slow" viruses; long interval between initial infection & onset of serious s&sx |
| Genes of Ribonucleic Acid (RNA) | only replicate inside of cells with CD4 antigens; use enzyme (reverse transcriptase) to convert its RNA to DNA |
| CD4 Cells aka Helper T-Cells | immune system leukocytes; seek out and attach to foreign bodies; HIV treatment and disease indicator (n=600-1500 cells/mL3 blood) |
| Seroconversion | antibodies produced in response to viral proteins, even if virus inactive |
| Viral load | amount of HIV in person; measured via blood count; changes during dif phases of disease; undetectable viral load early on |
| HIV transmission | Direct body fluid transmission required - blood, semen, vaginal/cervical secretions, CSF, breast milk, saliva |
| HIV Transmission - Sexual contact | virus afforded direct access to blood stream; virus infects mucosal lining macrophages; women>men to acquire HIV during intercourse;anal sex is most risky form unprotected sex;oral is least risky |
| HIV Transmission - Parenteral blood exposure | Virus has direct access to blood stream; IV drug use |
| HIV Transmission - Vertical Transmission | MOther to baby; during pregnancy, delivery or breast feeding Risk Reduction: antiretroviral drugs, C-section, formula fed; interventions decreased USA transmission from 25 to 2% |
| Post Exposure Prophylaxis (PEP) | Occupational health or emergency department - Goal: prevent establishment of HIV infection HIV testing (nurse & pt); Antiviral meds:2-3meds for 28 days - zidovudine (Retrovir;ZDV;AZT)+ lamivudine (Epivir,3TC) (single pill=Combivir); f/u testing |
| HIV Testing | 2006 CDC recommendations: WI: distinct concent; education & referral required; pts 13-654,all health care settings,preg women, pts starting Tb tx, Pts with STD dx, annual for high risk |
| HIV Testing - ELISA | Enzyme Linked Immunosorbent Assay (ELISA) - Initial test - tests for antibodies (not virus); up to 12 weeks for the test to be true positive; ELISA highly sensitive (99.5%) after 13 weeks |
| HIV Testing - Western Blot Assay | Test for antibodies; less prone to false positive results (99.9%); done to confirm + ELISA result; more reliable, expensive, time consuming than ELISA |
| HIV Testing - Rapid Screening Tests | Approved by FDA; OraQuick, multispot, Reveal, Uni-Gold; provide results in 15-30min; uses either whole blood or oral fluids; follow up ELISA and/or western blood suggested |
| HIV Clinical Manifestations | Initially virus affects T-Cells and macrophages; infected cells migrate to regional lymph tissue; within 4-10 days viral particles are releases into blood stream; brief intense period of viral replication; viral load = amount HIV actively replicating |
| Early Stage HIV | "Acute Retroviral Syndrome" - Days to weeks after exposure; S&Sx: resolve in 1-2 weeks: fever, pharyngitits, arthralgia, myalgia, anorexia, maculopapular rash, fatigue, lymphadenopathy, N/V, abd cramping, cephalgia - viral load is high |
| Latent Stage HIV | "Asymptomatic" - 3-10 years after acute phase (mean = 8-10 years); remain contagious; s/sx: none or lymphadenopathy - generalized persistent enlargement of >2 non-inguinal chain lymph nodes of unknown etiology |
| Transition Stage/Advanced HIV | "AIDS" - 3-10 years after acute phase; s/sx=generalized malaise, fatigue, fever, night sweats, unintended wt loss, dry skin or rashes, GI disturbances, AIDS-defining illness |
| Criteria for Transition Stage/Advanced HIV (AIDS) | seropositive for HIV; <200 CD4 cells/mm3 or <14% CD4 lymphocytes Opportunistic infection or disease - commonly a reactivation of an infection Generally not found in well-functioning immune system |
| AIDS Defining Illnesses | Candidiasis of bronchi,trachea, lungs or esopageal; invasive cervical Ca;encephalopathy; Herpes simplex; kaposi's sarcoma; lymphoma; mycobacterium Tb; recurrent pneumonia; toxoplasmosis of brain; wasting syndrome due to HIV |
| AIDS Clinical Manifestations | GI: nearly universal; possible target organ Pulmonary: major morbidity and mortality Cutaneous; Neurological: HIV invades early; Renal; Ocular: infectious & non-infectious; People with AIDS living longer: lung dz, rectal ca, kidney dz, DM, depression |
| AntiRetroviral Therapies (ART) | Changed HIV progression & Prognosis; Four main classes: NRTI, NNRTI, PI, and entry/fusion inhibitors; HAART: combinations; Goals: suppress infection (improve health); opportunistic infection prophylaxis; stim hematopoesis; treat AIDS defining illnesses |
| Nucleoside Reverese Transcriptase Inhibitors (NRTI) | Block reverse transcriptase enzyme; replication process 'decoys' (prevent RNA in DNA); slow HIV replication; Improve CD4 counts |
| Non-Neucleoside Reverse Transcriptase Inhibitors (NNRTI) | Works similar to NRTI; binds to dif site; improves CD4 counts; decreases viral load; only one NNRTI at a time |
| Protease Inhibitors (PI) | Prevents protease (enzyme) converting DNA to RNA; decreases viral load, slows HIV replication - lipodystrophy common: elevated cholesterol & trig, insulin resistance & DM, abd obesity w/ skeletal wasting; many med interactions & interferences |
| Entry Inhibitor aka Fusion Inhibitor | Resistant strains of HIV; prevents HIV from entering cells; blocks interaction of HIV surface proteins w/ CD4 cell surface; decreases viral load; increases CD4 count; ex. enfuvirtide (fuzeon), new in 2003, must reconstitute drug |
| CCR-5 Receptor Antagonist | Resistant strain of HIV;blocks HIV from attaching to CCR5 protein; ex. maraviroc (Selzentry); fewer side effects (esp neurophsych), favorable lipid profile, reduces inflammation, increases CD4 count more than other ARTS, new in 2007 |
| Integrase Inhibitors | ART - Prevents HIV DNA insertion in human DNA; sig reduction in viral load; administered with other ART, ex. ralegravir (Isentress), new in 2007 |
| Common Adverse Effects w/ ART's | N/V, hyperlipidemia, sedation, insulin resistance, DM, CAD, Periph neuropathy, nephrolithiasis, hypersensitivity reaction, diarrhea, anemia, insomnia, renal failure, lactic acidosis, pacnreatitis, hepatic toxicity, skin nodules |
| Highly Active Antiretroviral Therapy (HAART) | Combo of 3 categories: NRTI, NNRTI, PI; consist of atleast _ medications; sig decreases CD4; supresses viral load; "standard of care", do not start regimen until ready and capable of compliance |
| Monitoring of ART | Regular serology - CBC, liver, renal function, CD4, viral load; adherence to med regimen - med side effects, perceived barriers to adherence = physical, psychosocial, financial |
| Drug Resistance ART | NNRTI>NRTI>PI; related to inadequate dosing (many factors); testing for resistance - Genotypic & Phenotypic HIV Drug Resistance Assays |
| AIDS Dementia Complex | Direct effect of virus on brain; CNS infections & lesions including toxoplasmosis, non-hodgkins lymphoma, cryptococcal meningitis, CMV infections; children=prog encephalopathy w/ milestone reversal,cog/motor dysfunction |
| Cancer & AIDS | 30-40% of people with AIDS get cancer - Kaposi's Sarcoma; Lymphomas (esp Non-Hodgkins); Invasive cervical carcinoma; Cancers may be related to problem w/ immune system, damge to the immune system (disease &/or medications), meds |
| Nursing Diagnoses for AIDS | Ineffective coping r/t stigma, terminal illness; imbalance nutrition, less than body requirements r/t diarrhea, inability to prepare meals; Infeffective sexual patterns r/t unsafe sexual practives, imparied relationship w/ sig other |
Created by:
iloveraven
Popular Nursing sets